Ventyx adds advisors and delays trial data to Q1 2026
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street closes lower as oil prices jump, indexes notch monthly gains
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
- BofA turns S&P 500 signals from red to yellow: What to buy now
Ventyx Provides Clinical and Corporate Updates
December 2, 2025 7:02 AM ESTStrengthening our Advisory Board with addition of Mark McKenna as Strategic Advisor and Peter Libby, MD as a Clinical Advisor
Expanding the Phase 2 recurrent pericarditis study into Canada, EU and the UK to evaluate QD dose ranging in preparation for the global Phase 3 development plan
Interim analysis for the ongoing Phase 2 recurrent pericarditis study to now be presented as part of Ventyxs R&D Day planned for Q1 2026
SAN DIEGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq:... More
